Wordt geladen...
Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resistance, but the molecular mechanism remains unknown...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3732037/ https://ncbi.nlm.nih.gov/pubmed/23188630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0632 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|